Bright Minds Biosciences Inc. (DRUG)

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $229.40 million. The enterprise value is $189.17 million.

Market Cap	229.40M
Enterprise Value	189.17M

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025, before market open.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

DRUG has 7.08 million shares outstanding. The number of shares has increased by 39.99% in one year.

Current Share Class	7.08M
Shares Outstanding	7.08M
Shares Change (YoY)	+39.99%
Shares Change (QoQ)	+5.97%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	5.92
P/TBV Ratio	5.92
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 88.27, with a Debt / Equity ratio of 0.00.

Current Ratio	88.27
Quick Ratio	87.64
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-183.80

Financial Efficiency

Return on equity (ROE) is -11.21% and return on invested capital (ROIC) is -10.80%.

Return on Equity (ROE)	-11.21%
Return on Assets (ROA)	-10.57%
Return on Invested Capital (ROIC)	-10.80%
Return on Capital Employed (ROCE)	-9.54%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2,799.14% in the last 52 weeks. The beta is 0.23, so DRUG's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+2,799.14%
50-Day Moving Average	28.08
200-Day Moving Average	34.79
Relative Strength Index (RSI)	64.40
Average Volume (20 Days)	37,433

Short Selling Information

The latest short interest is 169,044, so 2.39% of the outstanding shares have been sold short.

Short Interest	169,044
Short Previous Month	164,650
Short % of Shares Out	2.39%
Short % of Float	5.67%
Short Ratio (days to cover)	2.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-3.71M
Pretax Income	-3.82M
Net Income	-2.40M
EBITDA	n/a
EBIT	-3.71M
Earnings Per Share (EPS)	-$0.44

Balance Sheet

The company has $38.74 million in cash and $115,905 in debt, giving a net cash position of $38.62 million or $5.45 per share.

Cash & Cash Equivalents	38.74M
Total Debt	115,905
Net Cash	38.62M
Net Cash Per Share	$5.45
Equity (Book Value)	38.78M
Book Value Per Share	5.48
Working Capital	38.74M

Cash Flow

Operating Cash Flow	-2.88M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-39.99%
Shareholder Yield	-39.99%
Earnings Yield	-1.04%
FCF Yield	n/a

Analyst Forecast

The average price target for DRUG is $83.25, which is 147.55% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$83.25
Price Target Difference	147.55%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.

Last Split Date	Jul 14, 2023
Split Type	Reverse
Split Ratio	1:5

Scores

Altman Z-Score	n/a
Piotroski F-Score	1